GSK plc GLAXF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.29B | 10.28B | 11.46B | 11.52B | 10.67B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.29B | 10.28B | 11.46B | 11.52B | 10.67B |
| Cost of Revenue | 2.78B | 2.52B | 3.48B | 3.02B | 2.89B |
| Gross Profit | 8.51B | 7.75B | 7.98B | 8.51B | 7.78B |
| SG&A Expenses | 2.94B | 2.81B | 3.55B | 2.92B | 2.85B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -273.85M | -828.58M | -577.21M | -689.04M | -328.61M |
| Total Operating Expenses | 7.80B | 6.55B | 9.29B | 7.37B | 7.47B |
| Operating Income | 3.49B | 3.73B | 2.17B | 4.16B | 3.20B |
| Income Before Tax | 475.22M | 2.89B | 1.26B | 3.31B | 2.52B |
| Income Tax Expenses | -267.14M | 410.92M | 296.58M | 420.70M | 321.94M |
| Earnings from Continuing Operations | 742.36M | 2.48B | 966.88M | 2.89B | 2.20B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -158.41M | -137.42M | -121.03M | -176.64M | -271.17M |
| Net Income | 583.95M | 2.34B | 845.86M | 2.71B | 1.93B |
| EBIT | 3.49B | 3.73B | 2.17B | 4.16B | 3.20B |
| EBITDA | 3.79B | 4.35B | 3.58B | 5.15B | 4.02B |
| EPS Basic | 0.15 | 0.58 | 0.21 | 0.67 | 0.47 |
| Normalized Basic EPS | 0.48 | 0.51 | 0.28 | 0.57 | 0.40 |
| EPS Diluted | 0.14 | 0.57 | 0.21 | 0.66 | 0.47 |
| Normalized Diluted EPS | 0.47 | 0.51 | 0.27 | 0.56 | 0.39 |
| Average Basic Shares Outstanding | 4.01B | 4.02B | 4.02B | 4.03B | 4.06B |
| Average Diluted Shares Outstanding | 4.06B | 4.07B | 4.09B | 4.10B | 4.11B |
| Dividend Per Share | 0.23 | 0.23 | 0.24 | 0.22 | 0.21 |
| Payout Ratio | 167.13% | 37.02% | 101.57% | 32.29% | 45.46% |